Clinical Research:
University of New Mexico Psilocybin in the Treatment of Alcoholism
Harbor - UCLA Psilocybin & Cancer
New York University Psilocybin & Cancer
Johns Hopkins University Psilocybin & Cancer
Psilocybin in the Treatment of Obsessive-Compulsive Disorder
Basic Science Research:
Heffter-Zürich Center Psilocybin-Serotonin Receptor Research
Johns Hopkins University Psilocybin & Spirituality
Preclinical Research:
Behavioral, Molecular and Genetic Research
ALL HEFFTER SUPPORTED
RESEARCH arrow
OUR BOARD OF DIRECTORS arrow

Harbor - UCLA Psilocybin & Cancer

divider

This is the first psychedelic treatment with terminally ill patients since the early 1970's. The study examines the use of psilocybin in a controlled setting to reduce the psychospiritual anxiety, depression, and physical pain of terminal cancer patients. As a society we spend a great deal of attention treating cancer, but very little treating the human being who is dying of cancer. This study treats the whole human being. It aims to help the patient move towards a 'good' death, and help the patient's family deal well with the dying process of their loved one. If we can learn to work more skillfully with dying, we will also learn to take better care of life.

The study of 12 subjects has been completed and published: Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. (2011) Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Arch Gen Psychiatry. 2011;68(1):71-78. doi:10.1001/archgenpsychiatry.2010.116. Dr. Charles Grob, M.D., a Heffter founder, directed the project.